Developability

Clinical drug development remains associated with a high failure rate, primarily to lack of efficacy, unmanageable toxicity, and suboptimal drug-like properties. These data indicate that, despite extensive optimization workflows, current strategies do not fully capture all determinants of clinical success.

Learn how monoclonal antibodies benefit from screening in development, covering biophysical properties, thermal stability, and machine learning drug discovery.

Explore how machine learning improves antibody developability, screening, and optimization by predicting biophysical properties and enhancing drug discovery outcomes.

Explore how computational predictors like SCM, TAP, and AlphaFold support therapeutic antibody development through AI-driven workflows and in silico tools.